Page URL:

DNA decoy drug, first of its kind, trialled in resistant melanoma

28 May 2012
Appeared in BioNews 658

A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial.

The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris, France. Rather than targeting a particular protein, enzyme or gene, these 'Dbait' drugs act as decoys within cancer cells, scrambling the internal signals which would otherwise enable the cells to repair themselves.

Designed to enhance the efficiency of conventional radiotherapy, DT01 appears safe and well-tolerated in patients with recurrent melanoma (an aggressive form of skin cancer) in a small dose-finding trial. The initial results suggest that DT01 acts specifically on tumours and does not increase the sensitivity of the rest of the skin to radiation.

DNA Therapeutics, the spin-out company now developing the Dbait drugs, further confirmed that 'responses have already been observed in the tumours treated by DT01 and radiotherapy, while no response [was observed] in the tumours treated by radiotherapy alone'.

Speaking to AFP, study leader Dr Christophe le Tourneau of the Institut Curie emphasised that the trial is a 'very, very early' one. Nonetheless, the results are likely to generate an upsurge in interest from biotech investors in DNA Therapeutics' unorthodox technology.

Dbait drugs would be administered to patients prior to a course of radio- or chemotherapy and are taken up by cancer cells in large quantities. The drugs' structure mimics a break in both DNA strands and is recognised by the cell's repair system as such. The result, a promotional video from DNA Therapeutics explains, 'is a fog of incoherent signals within the cell'.

'Acting like forgers, Dbait molecules make cancer cells treated with radiotherapy believe that they are far more severely damaged than they are', furthers Dr Marie Dutreix, who devised the Dbait concept and co-founded DNA Therapeutics. 'Accordingly, the tumour cells autodestruct'.

Should early tests of DT01 prove successful, the drug will progress to the next round of clinical trials designed to evaluate the efficiency of the treatment. DNA Technologies also hopes to start testing the drug in brain and liver cancer in combination with radio- or chemotherapy in 2013.

Cancer: des molécules "faussaires" pour doper l'effet de la radiothérapie
AFP |  23 May 2012
Dbait : une molécule à l'étude pour augmenter les effets de la radiothérapie |  23 May 2012
Des faussaires s’essaient contre le mélanome
Le Quotidien du Médecin |  23 May 2012
News and press releases 2012
DNA Therapeutics |  26 March 2012
Treatment for cancer: Dbait
YouTube (DNA Therapeutics) |  18 January 2012
16 November 2015 - by Meetal Solanki 
Researchers in the USA have mapped the sequence of genetic changes from early skin lesions, such as common moles, to malignant skin cancer...
2 November 2015 - by Arit Udoh 
The US Food and Drug Administration has approved a drug derived from a genetically modified herpes virus for the treatment of melanoma that cannot be removed by surgery...
13 August 2012 - by Dr Caroline Hirst 
Chemotherapy can produce a rogue response that eventually leads to tumours becoming resistant to treatment, scientists have found...
30 July 2012 - by Dr Zara Mahmoud 
Some cases of glioblastoma - a particularly aggressive form of brain cancer - may be due a genetic mutation where two separate genes fuse into one, scientists report...
11 June 2012 - by Dr Tamara Hirsch 
Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...
15 May 2012 - by Antony Starza-Allen 
Stem cells transplanted into the brain may offer protection against the side effects of chemotherapy, say US researchers...
26 March 2012 - by Sarah Pritchard 
A genetic test could be used to spare breast cancer patients from having to undergo postoperative chemotherapy...
27 February 2012 - by Dr Louisa Petchey 
The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span...
14 November 2011 - by Dr Louisa Petchey 
A new genetic test that will help to tailor drugs to cancer patients' individual tumours has been successfully trialled in the US...
8 June 2009 - by Dr Will Fletcher 
A new 'personalised' drug has been found to decrease the size of tumours in patients with advanced melanoma by 30 per cent. Results of an initial trial were presented at the meeting of the American Society of Clinical Oncology in Orlando, US. The results showed that the experimental treatment, a 'personalised' oral drug known as PLX4032, kept the melanoma at bay for six months. Pharmaceutical giant Roche and a privately owned company called Plexxikon Inc will carry out larger trials later thi...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.